BVT-0091-M001

Manumycin A
手霉素A

1 mg

BVT-0091-M005

5 mg

BVT-0091-M010

10 mg

BVT-0414

Dihydromanumycin A
二氢手霉素 A

1 mg

BVT-0264

Manumycin B
手霉素B

1 mg

BVT-0158

Deoxymanumycin A
法尼基转移酶

1 mg

BVT-0139

Rebeccamycin
瑞拜克

250 μg

1 mg

BVT-0100

Chrysomycin B
金黄霉素B

250 μg

1 mg

BVT-0099

Chrysomycin A
金黄霉素A

250 μg

1 mg

BVT-0095

Pyrrolcarbonyltaloside

1 mg

BVT-0070

Mutolide

1 mg

2.

Inhibitors of Rasfarnesyltransferases: F. Tamanoi; TIBS 18, 349 (1993), (Review)

3.

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic: J.B. Gibbs, et al.; Cell 77, 175 (1994)

4.

Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes: Y. Zou et al.; J. Biol. Chem. 271, 33592 (1996)

5.

Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells: A. Di Paolo, et al.; Br. J. Cancer 82, 905 (2000)

6.

Manumycin A and its analogues are irreversible inhibitors of neutral sphingomyelinase: C. Arenz, et al.; ChemBioChem 2, 141 (2001)

7.

Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells: M. She, et al.; Leukemia 19, 595 (2005)

8.

Binding of manumycin A inhibits IkappaB kinase beta activity: M. Bernier, et al.; J. Biol. Chem. 281, 2551 (2006)

9.

A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimetics: G. Porcu, et al.; Mol. Cancer 9:197 (2010)

10.

Targeting farnesyl-transferase as a novel therapeutcstrategy for mevalonate kinase defiency: In vitro and in vivo approaches: L. De Leo, et al.; Pharmacol. Res. 61, 506 (2010)

11.

Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice: K. Oana, et al.; Sci. Rep. 3, 2142 (2013)

12.

Manumycin induces apoptosis in prostate cancer cells: J.G. Li, et al., Onco Targets Ther. 7, 771 (2014)

13.

The natural tumorcide Manumycin-A targets protein phosphatase 1α and reduces hydrogen peroxide to induce lymphoma apoptosis. G.B. Carey, et al.; Exp. Cell. Res. 332, 136 (2015)

14.

Manumycin A from a new streptomyces strain induces endoplasmic reticulum stress-mediated cell death through specificity protein 1 signaling in human oral squamous cell carcinoma: C.J. Jae, et al.; Int. J. Oncol. 47, 1954 (2015)

15.

Manumycin A downregulates release of proinflammatory cytokines from TNF alpha stimulated human monocytes: E. Cecrdlova, et al.; Immunol. Lett. 169, 8 (2016)

16.

Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells: A. Datta, et al.; Cancer Lett. 408, 73 (2017)

17.

Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1): A. Tuladhar & K.S. Rein; ACS Med. Chem. Lett. 9, 318 (2018)

18.

The free fatty acid receptor 1 promotes airway smooth muscle cell proliferation through MEK/ERK and PI3K/Akt signaling pathways: A. Matoba, et al.; Am. J. Physiol. 314, 333 (2018)

19.

Effectors of thioredoxin reductase: Brevetoxins and manumycin-A: A. Tuladhar, et al.; Comp. Biochem. Physiol. C Toxicol. Pharmacol. 217, 76 (2019)

20.

Inhibiting extracellular vesicles formation and release: a review of EV inhibitors: M. Catalano & L. O'Driscoll; J. Etracell. Vesicles 9, 1703244 (2020)

21.

Combination of photoactive hypericin and Manumycin A exerts multiple anticancer effects on oxaliplatin-resistant colorectal cells: M. Macejova, et al.; Toxicol. Vitro 66, 104860 (2020)